Supply Chain

London-based rare disease drugmaker Shire divested its oncology business to the French drug company Servier for $2.4 billion, reports Reuters.

FDA Commissioner Gottleib recently stated at the February FDA Drug Supply Chain Security Act (DSCSA) public meeting that "Making sure that every link in the U.S. Drug Supply must be secure." and that, "Full implementation of the Drug Supply Chain…

After the Trump administration outlined a number of actions the federal government should take to address rising drug prices, two prescribing physicians argue these proposals may not only fail to lower drug prices, but also significantly limit Medicare patients' access to…

GlaxoSmithKline divested its portfolio of rare disease gene therapies to Orchard Therapeutics through a strategic agreement, the company announced April 12.

Here are the three latest drugs or medical devices approved by the FDA since March 23.

CVS Health tapped Marc-David Munk, MD, to serve as the CMO of MinuteClinic, the drugstore chain's retail medical clinic division and as the Associate CMO of CVS Health. 

An analysis by Sen. Cory Booker, D-N.J., suggests the nation's largest pharmaceutical companies do not plan to use new tax savings to lower prescription drug prices for consumers.

The generic drug industry, which supplies about 86 percent of the drugs prescribed in the U.S., is in a financial crisis — causing manufactures themselves to question the viability of the business, according to Bloomberg.  

With 83 percent of Americans worrying about the rising price of prescriptions, CVS Health will roll out a comprehensive tool that alerts pharmacists to cheaper drug options when they fill patients' prescriptions in an effort to reign in drug costs.

The FDA on April 11 approved IDx to market IDx-DR, a medical device that uses artificial intelligence to detect diabetic retinopathy.